Patterns of biologics use across treatment lines in elderly (Age >65) medicare patients with metastatic colon cancer

Oncologist

Volumn 21, Issue 6, 2016, Pages 676-683

  Bikov, Kaloyan A ^a   Mullins, Daniel C ^a   Hung, Anna ^a   Seal, Brian ^c   Onukwugha, Eberechukwu ^a   Hanna, Nader ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

Biologics; Cancer; Colon; Elderly; Medicare; Metastatic

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CHARLSON COMORBIDITY INDEX; DRUG APPROVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; VERY ELDERLY; COLONIC NEOPLASMS; METASTASIS; PATHOLOGY; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BEVACIZUMAB; BIOLOGICAL PRODUCTS; CETUXIMAB; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MEDICARE; NEOPLASM METASTASIS; UNITED STATES;

EID: 84975297677     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0199     Document Type: Article

References (19)

1. Genentech. Avastin (bevacizumab) prescribing information. Available at www.gene.com/download/pdf/avastin_prescribing.pdf. Accessed August 3, 2014.
2. U.S. Food and Drug Administration. Drugs@ FDA. Available at www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed August 3, 2014.
3. Bristol-Myers Squibb. Erbitux (cetuximab) prescribing information. Available at www.packageinserts.bms.com/pi/pi_erbitux.pdf. Accessed August 3, 2014.
4. Amgen. Vectibix (panitumumab) prescribing information. Available at www.pi.amgen.com/united_states/vectibix/vectibix_pi.pdf. Accessed August 3, 2014.
5. Gatzemeier U, Heller A, Foernzler D et al. Exploratory analyses EGFR, kRAS mutations and othermolecularmarkers in tumors ofNSCLC patients (pts) treated with chemotherapy 1/2 erlotinib (TALENT). J Clin Oncol 2005;23(Suppl 16S):7028.
6. Kris MG, Sandler A, Miller VA et al. EGFR and KRASmutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. J Clin Oncol 2005;23(Suppl 16S): 7029.
7. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
8. Liévre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995.
9. Di Fiore F, Le Pessot F, Lamy A et al. KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer. J Clin Oncol 2007;25(Suppl 18S):10502.
10. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237.
11. Finocchiaro G, Cappuzzo F, Janne PA et al. EGFR, HER2 and KRAS as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 2007;25(Suppl 18S):4021.
12. Neumann J, Zeindl-Eberhart E, Kirchner T et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009;205:858-862.
13. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
14. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3.2014. Available at www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed June 10, 2014.
15. Sanoff HK, Goldberg RM. How we treat metastatic colon cancer in older adults. J Geriatr Oncol 2013;4:295-301.
16. McCleary NJ, Dotan E, Browner I. Refining the chemotherapy approach for older patients with colon cancer. J Clin Oncol 2014;32:2570-2580.
17. Bikov KA, Mullins CD, Seal B et al. Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare. Med Care 2013.
18. Zafar SY, Marcello JE, Wheeler JL et al. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 2009; 5:228-233.
19. Hess GP, Wang PF, Quach D et al. Systemic therapy formetastatic colorectal cancer: Patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 2010;6: 301-307.